All In Biotech

Drug Trial Radar · NCT04257110

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

A First-in-human, Open Label, Multiple Dose, Dose Escalation and Cohort Expansion Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jul 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

117

Actual

Start

Jul 28, 2020

Primary completion

Aug 31, 2024

Study completion Dec 31, 2024

Sponsor

Sponsor type
Industry
First posted
Feb 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, first-in-human (FIH), phase 1 dose-escalation and cohort expansion study of BB-1701 in subjects with locally advanced/metastatic HER2 expressing solid tumors. The study consists of 2 parts: dose-escalation (Part 1) and cohort expansion (Part 2). Part 1 consists of dose escalation cohorts for determining the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Part 2 consists of expansion cohorts, including but not limited to breast cancer, gastric/gastroesophageal junction cancer, bladder cancer and colon cancer, for exploring 1 or more RP2Ds or schedules for expanding/deepening the information/knowledge about clinical safety, clinical pharmacokinetics and anti-tumor activity.

Conditions

  • Locally Advanced/Metastatic HER2 Positive Solid Tumors

Interventions

  • BB-1701Drug

    BB-1701 will be administered as an intravenous infusion, every 3 weeks or every 4 weeks or every 6 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with adverse events and serious adverse eventsTime frame: up to 2 years
  2. Number of subjects with dose limiting toxicity (DLT)Time frame: Cycle 1. Duration of each cycle is 21 days.
  3. MTDTime frame: Cycle 1. Duration of each cycle is 21 days.

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Sarah Cannon Research

    Nashville, Tennessee

  • The Regents of NEXT Virginia, LLC

    Fairfax, Virginia

  • Cancer Hospital Chinese Academy of Medical Science

    Beijing, China

  • Sun Yat-sen Memorial Hospital

    Guangzhou, China

  • The First Affiliated Hospital of Zhejiang University

    Hangzhou, China

  • Sir Run Run Shaw Hospital - Zhejiang University School of Medicine

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hanzhou, China

  • Linyi Cancer Hospital

    Linyi, China

  • Hubei Cancer Hospital

    Wuhan, China

  • Jiangsu Province Hospital

    Nanjin, Jiangsu, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.